Posted by Michael Wonder on 26 Sep 2019
Migraine drug not cost effective NICE says in final draft guidance
26 September 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in final draft guidance published today.
The draft guidance looks at erenumab (also called Aimovig and made by Novartis) for preventing chronic and episodic migraine in adults who have 4 episodes or more of migraine every month and where at least 3 other preventive treatments haven’t worked.
Costing around £5,000 per patient per year at its list price, erenumab targets the process by which proteins cause blood vessels in the brain to swell, leading to the symptoms associated with migraines. It is given every 4 weeks as a self-administered injection.
